Pharmaceutical care for a patient with rhino-orbito-cerebral mucormycosis
- VernacularTitle:1例鼻-眶-脑型毛霉菌病患者的药学监护
- Author:
Xia WU
1
;
Yinlong ZHAO
2
;
Zhiqing ZHANG
1
;
Weichong DONG
1
Author Information
1. Dept. of Pharmacy，the Second Hospital of Hebei Medical University，Shijiazhuang 050051，China
2. ICU，Department of Anesthesiology，the Second Hospital of Hebei Medical University，Shijiazhuang 050051，China
- Publication Type:Journal Article
- Keywords:
rhino-orbito-cerebral mucormycosis;
amphotericin B colloidal dispersion;
posaconazole;
therapeutic drug
- From:
China Pharmacy
2024;35(12):1533-1538
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To provide ideas for clinical diagnosis， treatment and pharmaceutical care of rhino-orbito-cerebral mucormycosis （ROCM）. METHODS The diagnosis and treatment of 1 case of ROCM in which clinical pharmacists participated were analyzed. Combined with treatment guidelines， the actual situation of drug accessibility and economy， clinical pharmacists recommend amphotericin B colloidal dispersion in combination with posaconazole to treat fungal infections. The clinical efficacy， liver and kidney function and electrolytes were monitored. To increase the local concentration of amphotericin B deoxycholate （AmB-D）， clinical pharmacists assisted physicians in determining the dosage and formulation of AmB-D for intrathecal injection， intranasal and eye drops based on the results of blood and cerebrospinal fluid examinations. In response to the situation that the plasma trough concentration of posaconazole had not reached the target， clinical pharmacists recommended that Posaconazole oral suspension was replaced with Posaconazole enteric-coated tablets， and provided the patient with therapeutic drug monitoring （TDM）， individualized medication guidance， and long-term follow-up after discharge. RESULTS The clinician adopted the advice of the clinical pharmacists. After treatment， the patient was discharged from the hospital with medicine after her condition improved. CONCLUSIONS Clinical pharmacists develop individualized treatment protocols for ROCM patients by adjusting dose and dosage forms， providing medication monitoring and TDM to ensure the safety of drug use for patients.
